Apogee Therapeutics IncAPGE
Price$135.07

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$294.4MTTM through 30 Jun 2026
Free Cash Flow -$249MTTM through 30 Jun 2026

Margins

Current

Returns

-5.9%ROE
-5.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio32.59x
Net Debt-$1.1Bnet cash position
Cash & Equivalents$105.6M

Quality Metrics

Altman Z-Score75.94
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Diluted EPS-$4.34TTM
'22'23'24'25
FY2025: $-4.22

Dividend

No dividend

Capital Allocation

R&D Spend$240.7M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.